Ambry Genetics Announces Certified Service Provider Status for Agilent Microarrays
The Certified Service Provider program comprises a select list of strategic organizations that pass a rigorous assessment to use Agilent's microarray platform. The program combines the provider's focused expertise with the complete Agilent microarray workflow to create specialized services or complete genomic research solutions.
"We are thrilled to be the first Agilent Certified Service Provider on the West Coast of the United States," said Ardy Arianpour, Director of Business Development, Pharmaceutical Services at Ambry Genetics. "Our Pharmaceutical, Biotech, and Academic customers will be able to receive the highest quality results and service with the CSP stamp of approval. This accomplishment continues to demonstrate Ambry Genetics' dedication to our customers and the genomics services industry."
"Array comparative genomic hybridization has become the approach of choice in research settings to comprehensively identify chromosomal imbalances throughout the genome," added Dr. Aaron Elliott, R&D Scientist, Ambry Genetics. "Agilent's wide variety of catalog arrays combined with a cost effective custom design capability available through Agilent's eArray software allows us to provide our researchers with highly sensitive genome-wide scans at varying resolutions. Our CSP status further ensures our researchers that they are getting the best quality service available."
About Agilent Technologies - www.agilent.com
Agilent Technologies Inc. (NYSE: A) is the world's premier measurement company and a technology leader in communications, electronics, life sciences and chemical analysis. The company's 18,000 employees serve customers in more than 110 countries. Agilent had net revenues of $5.8 billion in fiscal 2008.
Ambry Genetics is a CAP-accredited, GLP-compliant, CLIA-certified commercial clinical laboratory headquartered in Aliso Viejo, California. Since the company's inception in 2000, it has become a leader in providing genetic services focused on clinical diagnostics, pharmacogenomics and research support services. Ambry has built a solid reputation for unparalleled service, and has been at the forefront of applying new technologies to the clinical molecular diagnostics market and advancements in disease research. To learn more about testing and services available through Ambry, visit www.ambrygen.com.